You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
A New VISTA on combination therapy for negative checkpoint regulator blockade
|
---|---|
Published in |
Journal for Immunotherapy of Cancer, December 2016
|
DOI | 10.1186/s40425-016-0190-5 |
Pubmed ID | |
Authors |
Jie Deng, Isabelle Le Mercier, Anna Kuta, Randolph J. Noelle |
Abstract |
Negative checkpoint regulators function to restrain T cell responses to maintain tolerance and limit immunopathology. However, in the setting of malignancy, these pathways work in concert to promote immune-mediate escape leading to the development of a clinically overt cancer. In the recent years, clinical trials demonstrating the efficacy of blocking antibodies against these molecules have invigorated the field of immunotherapy. In this review, we discuss the current understanding on established NCR blockade and how strategic combination therapy with anti-VISTA antibody can be used to target multiple non-redundant NCR pathways. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 60% |
Unknown | 2 | 40% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 60% |
Scientists | 1 | 20% |
Science communicators (journalists, bloggers, editors) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
France | 1 | 1% |
Unknown | 75 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 17 | 22% |
Other | 10 | 13% |
Student > Master | 10 | 13% |
Student > Ph. D. Student | 8 | 11% |
Student > Bachelor | 7 | 9% |
Other | 9 | 12% |
Unknown | 15 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Immunology and Microbiology | 15 | 20% |
Agricultural and Biological Sciences | 11 | 14% |
Biochemistry, Genetics and Molecular Biology | 10 | 13% |
Medicine and Dentistry | 10 | 13% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
Other | 10 | 13% |
Unknown | 16 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 May 2021.
All research outputs
#3,009,905
of 25,377,790 outputs
Outputs from Journal for Immunotherapy of Cancer
#828
of 3,421 outputs
Outputs of similar age
#56,637
of 422,907 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#10
of 31 outputs
Altmetric has tracked 25,377,790 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,421 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 422,907 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.